Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bioventus (BVS) Other financing activities (2020 - 2025)

Bioventus (BVS) has disclosed Other financing activities for 6 consecutive years, with -$208000.0 as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Other financing activities fell 7.22% year-over-year to -$208000.0, compared with a TTM value of -$827000.0 through Dec 2025, down 9.1%, and an annual FY2025 reading of -$827000.0, down 9.1% over the prior year.
  • Other financing activities was -$208000.0 for Q4 2025 at Bioventus, roughly flat from -$207000.0 in the prior quarter.
  • Across five years, Other financing activities topped out at $4.0 million in Q4 2023 and bottomed at -$209000.0 in Q2 2025.
  • Average Other financing activities over 5 years is $103800.0, with a median of -$83000.0 recorded in 2023.
  • Peak annual rise in Other financing activities hit 99775.0% in 2023, while the deepest fall reached 983.33% in 2023.
  • Year by year, Other financing activities stood at $28000.0 in 2021, then crashed by 85.71% to $4000.0 in 2022, then skyrocketed by 99775.0% to $4.0 million in 2023, then plummeted by 104.86% to -$194000.0 in 2024, then fell by 7.22% to -$208000.0 in 2025.
  • Business Quant data shows Other financing activities for BVS at -$208000.0 in Q4 2025, -$207000.0 in Q3 2025, and -$209000.0 in Q2 2025.